ANTIBODY-DRUG (ADC)
\nCHARACTERIZATION SERVICE<\/h1><\/h1><\/div>Phase-Appropriate ADC Characterization for Development, Comparability, Validation, and Commercialization
\n<\/strong>
\nAntibody-drug conjugates (ADCs) combine the molecular complexity of biologics with the potency of highly active small-molecule payloads. Variability in drug-to-antibody ratio (DAR), aggregation, charge heterogeneity, glycosylation, and free payload levels can directly impact safety, efficacy, pharmacokinetics, and comparability. Effective antibody drug conjugate analysis requires robust characterization of relevant quality attributes, and product-specific definition of critical quality attributes (CQAs).<\/p>\nAt nuvalore<\/strong>, we provide ADC characterization and GMP-aligned analytical services to help sponsors characterize, monitor, and control CQAs throughout development, comparability assessments, validation, and commercialization.<\/p>\nOur capabilities include DAR analysis, charge variant analysis, peptide mapping, impurity profiling, and GMP quality control testing. Orthogonal ADC characterization can integrate chromatographic, electrophoretic, and mass spectrometry-based approaches, depending on the analytical question, product complexity, and stage of development.<\/p>\n
By combining orthogonal analytical techniques, Quality by Design (QbD) principles<\/a>, and GMP execution, we help sponsors generate reliable data, support informed comparability decisions, and advance ADC programs with confidence.<\/p>\n<\/div>Discuss Your ADC Program<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Why ADC Characterization Matters<\/h2>\n
Robust ADC analytical characterization is essential to:<\/p>\n
\n- Understand and control ADC heterogeneity<\/li>\n
- Support stability and comparability assessments<\/a><\/li>\n
- Monitor product consistency throughout development<\/li>\n
- Generate data suitable for validation and GMP quality control<\/li>\n
- Build confidence in regulatory submissions and lifecycle management<\/li>\n<\/ul>\n
As ADC programs advance from early development into validation, stability studies, and commercial manufacturing, analytical requirements become increasingly demanding. Phase-appropriate analytical strategies help ensure methods remain fit-for-purpose throughout the product lifecycle.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
Supporting ADC Programs Across the Lifecycle<\/h2>\n<\/div>\n\n\n\n\tEarly Development<\/th> Clinical Development<\/th> Commercial Readiness<\/th>\n<\/tr>\n<\/thead>\n \n\n\tProduct characterization<\/td> Stability studies<\/td> Method validation<\/td>\n<\/tr>\n \n\tCQA identification<\/td> Method qualification<\/td> Method transfer<\/td>\n<\/tr>\n \n\tMethod Development<\/a><\/td> Comparability assessments<\/td> GMP QC testing<\/td>\n<\/tr>\n \n\tEarly stability assessments<\/td> Process monitoring<\/td> Release support<\/td>\n<\/tr>\n \n\tConjugation characterization<\/td> Characterization of development batches<\/td> Ongoing stability programs<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/div>ADC Physicochemical Characterization Built Around Product-Relevant Quality Attributes<\/p>\n<\/div>
\n\n\n\n\tAnalytical Focus Area<\/th> Critical Quality Attribute (CQA)<\/th> Why It Matters<\/th> Primary Analytical Techniques<\/th>\n<\/tr>\n<\/thead>\n \n\n\tDrug-to-Antibody Ratio (DAR)<\/td> DAR average & DAR distribution<\/td> A major determinant of the efficacy-toxicity balance and a key indicator of conjugation consistency, product stability, and lot-to-lot reproducibility<\/td> HIC-HPLC, RP-HPLC, LC-MS*<\/td>\n<\/tr>\n \n\tSize Variants & Purity<\/td> Aggregates, fragments, and purity<\/td> Aggregation and fragmentation can impact safety, pharmacokinetics, and immunogenicity risk; critical for release, stability, and product consistency<\/td> SEC-HPLC, CE-SDS, SEC-MALS<\/td>\n<\/tr>\n \n\tCharge Variant Analysis<\/td> Charge heterogeneity<\/td> Sensitive indicator of conjugation-induced heterogeneity and process consistency; supports stability studies, comparability assessments, and lifecycle monitoring<\/td> icIEF, CEX<\/td>\n<\/tr>\n \n\tIdentity & Primary Structure<\/td> Identity confirmation and PTM trending<\/td> Verifies molecular integrity, monitors PTM trends, and supports stability, comparability, and root-cause investigations<\/td> UV-RP-HPLC Peptide Mapping, LC-MS*<\/td>\n<\/tr>\n \n\tFree Payload & Related Impurities<\/td> Unconjugated payload and degradation products<\/td> Critical for controlling toxicity risk and supporting release and stability testing<\/td> Payload-related impurity profiling using fit-for-purpose chromatographic methods<\/td>\n<\/tr>\n \n\tGlycosylation Profiling<\/td> N-glycosylation patterns<\/td> Glycosylation can influence Fc-mediated functions and alter charge or hydrophobicity profiles, supporting process consistency monitoring and comparability assessments<\/td> Released glycan profiling by RP-HPLC, HILIC <\/td>\n<\/tr>\n \n\tMass Spectrometry Characterization<\/td> PTMs, DAR species, conjugation site, structural integrity<\/td> Provides high-resolution characterization of ADC heterogeneity, supporting DAR species analysis, conjugation site assessment, PTM monitoring, root-cause investigations, and high-confidence comparability assessments<\/td> LC-MS*, Subunit LC-MS*, Native LC-MS*, Reduced LC-MS*<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/div>*LC-MS capabilities are currently being expanded as part of nuvalore’s <\/b>analytical platform development. Please contact us to discuss project-specific requirements.<\/p>\n<\/div><\/div><\/div><\/div><\/div>Comparability-Ready Analytical Strategies<\/h2>\n
Process changes, manufacturing scale-up, site transfers, formulation updates, and lifecycle improvements all require robust comparability assessments.<\/p>\n
nuvalore <\/b>designs comparability-ready analytical strategies that evaluate critical quality attributes across multiple dimensions of product quality. By combining complementary analytical approaches, we help sponsors assess the impact of process changes, demonstrate product consistency, and support informed development and commercialization decisions.<\/p>\n
Our analytical strategies support alignment with:<\/p>\n
\n- ICH Q5E (Comparability)<\/li>\n
- ICH Q6B (Specifications)<\/li>\n
- ICH Q2(R2) (Validation)<\/li>\n
- ICH Q14 (Analytical Procedure Development)<\/li>\n
- EU GMP expectations<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
GMP Quality Control & Release Testing<\/h2>\n
Beyond analytical characterization, nuvalore <\/b>supports GMP quality control and release testing activities required for clinical and commercial ADC drug products.<\/p>\n
Our capabilities include:<\/p>\n
\n- Appearance<\/li>\n
- Color<\/li>\n
- pH<\/li>\n
- Conductivity<\/li>\n
- Osmolality<\/li>\n
- Visible particles<\/li>\n<\/ul>\n
\nCHARACTERIZATION SERVICE<\/h1><\/h1><\/div>
Phase-Appropriate ADC Characterization for Development, Comparability, Validation, and Commercialization At nuvalore<\/strong>, we provide ADC characterization and GMP-aligned analytical services to help sponsors characterize, monitor, and control CQAs throughout development, comparability assessments, validation, and commercialization.<\/p>\n Our capabilities include DAR analysis, charge variant analysis, peptide mapping, impurity profiling, and GMP quality control testing. Orthogonal ADC characterization can integrate chromatographic, electrophoretic, and mass spectrometry-based approaches, depending on the analytical question, product complexity, and stage of development.<\/p>\n By combining orthogonal analytical techniques, Quality by Design (QbD) principles<\/a>, and GMP execution, we help sponsors generate reliable data, support informed comparability decisions, and advance ADC programs with confidence.<\/p>\n<\/div> Robust ADC analytical characterization is essential to:<\/p>\n As ADC programs advance from early development into validation, stability studies, and commercial manufacturing, analytical requirements become increasingly demanding. Phase-appropriate analytical strategies help ensure methods remain fit-for-purpose throughout the product lifecycle.<\/p>\n<\/div><\/div><\/div><\/div><\/div> ADC Physicochemical Characterization Built Around Product-Relevant Quality Attributes<\/p>\n<\/div> *LC-MS capabilities are currently being expanded as part of nuvalore’s <\/b>analytical platform development. Please contact us to discuss project-specific requirements.<\/p>\n<\/div><\/div><\/div><\/div><\/div> Process changes, manufacturing scale-up, site transfers, formulation updates, and lifecycle improvements all require robust comparability assessments.<\/p>\n nuvalore <\/b>designs comparability-ready analytical strategies that evaluate critical quality attributes across multiple dimensions of product quality. By combining complementary analytical approaches, we help sponsors assess the impact of process changes, demonstrate product consistency, and support informed development and commercialization decisions.<\/p>\n Our analytical strategies support alignment with:<\/p>\n Beyond analytical characterization, nuvalore <\/b>supports GMP quality control and release testing activities required for clinical and commercial ADC drug products.<\/p>\n Our capabilities include:<\/p>\n
\n<\/strong>
\nAntibody-drug conjugates (ADCs) combine the molecular complexity of biologics with the potency of highly active small-molecule payloads. Variability in drug-to-antibody ratio (DAR), aggregation, charge heterogeneity, glycosylation, and free payload levels can directly impact safety, efficacy, pharmacokinetics, and comparability. Effective antibody drug conjugate analysis requires robust characterization of relevant quality attributes, and product-specific definition of critical quality attributes (CQAs).<\/p>\nWhy ADC Characterization Matters<\/h2>\n
\n
Supporting ADC Programs Across the Lifecycle<\/h2>\n<\/div>
\n\n
\n\t \nEarly Development<\/th> Clinical Development<\/th> Commercial Readiness<\/th>\n<\/tr>\n<\/thead>\n \n\t Product characterization<\/td> Stability studies<\/td> Method validation<\/td>\n<\/tr>\n \n\t CQA identification<\/td> Method qualification<\/td> Method transfer<\/td>\n<\/tr>\n \n\t Method Development<\/a><\/td> Comparability assessments<\/td> GMP QC testing<\/td>\n<\/tr>\n \n\t Early stability assessments<\/td> Process monitoring<\/td> Release support<\/td>\n<\/tr>\n \n\t Conjugation characterization<\/td> Characterization of development batches<\/td> Ongoing stability programs<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/div> \n\n
\n\t \nAnalytical Focus Area<\/th> Critical Quality Attribute (CQA)<\/th> Why It Matters<\/th> Primary Analytical Techniques<\/th>\n<\/tr>\n<\/thead>\n \n\t Drug-to-Antibody Ratio (DAR)<\/td> DAR average & DAR distribution<\/td> A major determinant of the efficacy-toxicity balance and a key indicator of conjugation consistency, product stability, and lot-to-lot reproducibility<\/td> HIC-HPLC, RP-HPLC, LC-MS*<\/td>\n<\/tr>\n \n\t Size Variants & Purity<\/td> Aggregates, fragments, and purity<\/td> Aggregation and fragmentation can impact safety, pharmacokinetics, and immunogenicity risk; critical for release, stability, and product consistency<\/td> SEC-HPLC, CE-SDS, SEC-MALS<\/td>\n<\/tr>\n \n\t Charge Variant Analysis<\/td> Charge heterogeneity<\/td> Sensitive indicator of conjugation-induced heterogeneity and process consistency; supports stability studies, comparability assessments, and lifecycle monitoring<\/td> icIEF, CEX<\/td>\n<\/tr>\n \n\t Identity & Primary Structure<\/td> Identity confirmation and PTM trending<\/td> Verifies molecular integrity, monitors PTM trends, and supports stability, comparability, and root-cause investigations<\/td> UV-RP-HPLC Peptide Mapping, LC-MS*<\/td>\n<\/tr>\n \n\t Free Payload & Related Impurities<\/td> Unconjugated payload and degradation products<\/td> Critical for controlling toxicity risk and supporting release and stability testing<\/td> Payload-related impurity profiling using fit-for-purpose chromatographic methods<\/td>\n<\/tr>\n \n\t Glycosylation Profiling<\/td> N-glycosylation patterns<\/td> Glycosylation can influence Fc-mediated functions and alter charge or hydrophobicity profiles, supporting process consistency monitoring and comparability assessments<\/td> Released glycan profiling by RP-HPLC, HILIC <\/td>\n<\/tr>\n \n\t Mass Spectrometry Characterization<\/td> PTMs, DAR species, conjugation site, structural integrity<\/td> Provides high-resolution characterization of ADC heterogeneity, supporting DAR species analysis, conjugation site assessment, PTM monitoring, root-cause investigations, and high-confidence comparability assessments<\/td> LC-MS*, Subunit LC-MS*, Native LC-MS*, Reduced LC-MS*<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/div> Comparability-Ready Analytical Strategies<\/h2>\n
\n
GMP Quality Control & Release Testing<\/h2>\n
\n